Philip Morris
Wlf Off-Label Use Suit Heats Up
Fields
- Type
- NELE, NEWSLETTER
- Attachment
- 2046936799/2046936802
- Area
- NICOLI,DAVID/OFFICE
- Site
- W6
- Named Person
- Samp, R.
- Taylor, M.
- Request
- Stmn/R1-072
- Stmn/R1-079
- Document File
- 2046936725/2046937271/Missing
- Named Organization
- FDA, Food and Drug Administration
- Fdir
- Federal Court
- Federal Register
- Media Inst
- Radio + Television News Directors Assn
- Supreme Court
- Thomas Jefferson Center for the Protecti
- Wlf, Washington Legal Foundation
- Assn of American Publishers
- Chief Counsel
- Fdir
- Author (Organization)
- FDA, Food and Drug Administration
- Food + Drug Insider Report
- Litigation
- Stmn/Produced
- Master ID
- 2046936726/6992
Related Documents:- 2046936726 Table of Contents
- 2046936727 A
- 2046936728-6731 FDA's Legally Suspect Actions Invite Challenge
- 2046936732-6735 FDA Paralysis Raises Health Care Costs
- 2046936736-6739 the Real Problem with Health Care in America: While Dr. David Kessler's FDA Fiddles, Medical Approvals Lag and Americans Die
- 2046936740-6743 What the FDA Doesn't Want You to Know Could Kill You
- 2046936744-6751
- 2046936752-6759
- 2046936760-6762 Guide to Medical Device Regulation FDA Issues First Warning Letter Citing Gmp Problems Under New Cpg
- 2046936763-6766 the Vitamin Uprising
- 2046936767-6780 Losing the Edge Overseas Patients Reap the Benefits of U.S.Research While Those Here Wait
- 2046936781-6783 Losing the Edge
- 2046936784 Feds: Toughen Regulation, Promote Research Improvements Needed, and They Are on the Way
- 2046936785-6786
- 2046936787-6789 Challenging FDA Authority
- 2046936790-6793 Speakeasies in A New Age of Prohibition
- 2046936794-6798 Who Is Happiest Politician in Washington Over Whitewater? Alfonse D'amato - Newt Gingrich - David Kessler?
- 2046936799-6800 Pro-Free Enterprise Group Challenges FDA's Authority to Regulate Drug Companies' Speech
- 2046936803-6805 Just Call Me 'doc'
- 2046936806-6810 Food and Drugs and Politics
- 2046936811-6813 Science and Technology Getting the Lead Out
- 2046936814 Forbes Fear of Falling 5 Ways to Protect Yourself in Scary Times
- 2046936815-6816 Book Burning
- 2046936817 If A Murderer Kills You, It's Homicide If A Drunk Driver Kills You, It's Manslaughter If the FDA Kills You, It's Just Being Cautious
- 2046936818-6820 Frustration for Medical Innovators
- 2046936821 Block That Innovation
- 2046936822-6823 Getting Even
- 2046936824-6826 Biotech Pipeline: Bottleneck Ahead
- 2046936827-6829 Consuming Interest Are We Safe From the FDA?
- 2046936830-6839 Saying Yes to Drugs Policy Analysis
- 2046936840-6858 Deadly Overcaution: FDA's Drug Approval Process
- 2046936859 B
- 2046936860-6861 Litigation Update Wlf Wins Suit Against FDA to Stop Overregulation of Heart Valves (Washington Legal Foundation V. Shalala)
- 2046936862-6863 Litigation Update Wlf Opposes FDA Efforts to Dismiss First Amendment Lawsuit (Washington Legal Foundation V. Kessler)
- 2046936864-6867 Dickinson's FDA Review
- 2046936868-6869 Wlf Urges Appeals Court to Enjoin Federal Policy Restricting Human Heart Valve Transplant (Washington Legal Foundation V. Shalala)
- 2046936870-6871 FDA Problems Slow US Andas
- 2046936872-6873 Taking the Heat An Aids Patient Champions A Risky Blood Treatment Banned in the U.S.
- 2046936874-6876 New Study Says Breast Implants Are Not A Health Risk
- 2046936877-6878 Wlf Sues FDA to Overturn Policy Restricting Information on Off-Labels Uses of Approved Drugs and Devices (Washington Legal Foundation V. Shalala)
- 2046936879 Ex-Inspector of F.D.A. Is Convicted of Bribery
- 2046936879A FDA Has No Position Yet
- 2046936880-6881 M-D-D-I Reports - 'the Gray Sheet'
- 2046936882 FDA Halts Test on Device That Shows Promise for the Victims of Cardiac Arrest
- 2046936883 Law Concerning Medical Devices Is Often Ignored
- 2046936884 Dairies, Drugs and Accusations
- 2046936884A FDA to Launch Campaign on New Labels for Food
- 2046936885 Probe of Three FDA Officials Sought Industry Ties Before Approval of Bovine Growth Hormone Are at Issue
- 2046936886-6889 Safety First How A Device to Aid in Breast Self-Exams If Kept Off the Market Other Nations Approved It But U.S. Demands Proof Simple Pad Isn't Risky Nine Year Battle with the FDA
- 2046936890-6892 Who Will Regulate the Regulators? If You Make A Mistake, Shouldn't You Own Up? Not If You're the FDA, Epa, or Ftc
- 2046936893-6894 None - A - Day Is the FDA Out to Take Your Vitamin?
- 2046936895 Will A New Government Program Net the Bad Fish?
- 2046936896-6897 FDA Responds to Wlf Petition Regarding Off-Label Drug Use by Indefinitely Postponing Issuance of Regulatory Guidelines
- 2046936898-6905 FDA Research: Overview
- 2046936906-6910 Government Report Finds Levels Safe Pesticide Residues in Your Children's Food
- 2046936911-6912 Wlf Urges FDA to Rescind Policy Restricting Information Flow on Off-Label Uses of Approved Drugs and Devices
- 2046936913 Regulatory Chokehold FDA Red Tape Dooms Transplant Drug
- 2046936914 FDA Called Lax in Overseeing Medical Sterilizers, Disinfectants
- 2046936915 FDA Sets Labeling Rules for Dietary Supplements Nutritional Data, Support for Health Claims Required
- 2046936916 Chemicals That Taint Seafood Concerns Continue Over Safety of Methylmercury Inspection Processes
- 2046936917 Lifesaving Devices Languish at the FDA
- 2046936918-6919 Wlf Sues FDA to Enjoin Federal Policy Restricting Human Heart Valve Transplants (Washington Legal Foundation V. Shalala)
- 2046936920 What's in Food? Answers Differ at 2 Agencies Manufacturers Fight to Keep FDA Label Rules From Encroaching on Ftc Ad Rules
- 2046936921 Reform the FDA
- 2046936922 Legal Beat FDA Approval Shield Firms in Injury Suits
- 2046936923 Water From A Bottle
- 2046936924 Commentary FDA and Our Split Medical Persona
- 2046936925-6926 FDA Assailed for Slow Testing of New Drugs
- 2046936927 Andrews Office Products Capitol Heights, Md (K)
- 2046936928-6947 Statement by David A. Kessler, M.D. Commissioner of Food and Drugs Before the Committee on Energy and Commerce Subcommittee on Health and the Environment U.S. House of Representatives
- 2046936948-6961 Filthy Food,Dubious Drugs, and Defective Devices: the Legacy of FDA's Antiquated Statute A Staff Report
- 2046936962-6968 Gao Reports on FDA-Related Topics 860000 to Present
- 2046936969 D
- 2046936970-6985 Statement by Louis W. Sullivan, M.D. Secretary of Health and Human Services Before the Committee on Labor and Human Resources U.S. Senate on the Final Report of the Advisory Committee on the FDA
- 2046936986-6992 Proposed Remarks of Dr. Charles Edwards Before the Senate Committee on Labor and Human Resources
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- rmt92e00
Document Images
I
J
September 30, 1994
both providers and recipients of such
information.
Although the FDA has not attempted to interfere
with off-label uses of FDA-approved drugs and
medical devices, within the past two years the
agency has taken steps to interfere with the
dissemination of truthful information about off-
label uses. In one particular case, FDA blocked
a manufacturer's attempt to distribute to doctors
a medical textbook simply because the textbook
contained truthful information regarding
generally-accepted off-label uses of the
manufacturer's cancer-treating drugs.
As the Washington Legal Foundation's (WLF)
offensive against FDA's off-label use policy
approaches its first-year anniversary, it finally
looks like a federal court will have the
opportunity to deliver a dose of reality to one or
the other of the two adversaries.
The WLF is a Washington, D.C.-based legal
advocacy outfit that relishes tangling with
government agencies who interfere with the
rights of business interests to be about the
business of free
filed a
" C i t i z e n s
Petition" with
FDA last
O c t o b e r
demanding
that FDA
rescind its
November
1992 draft
p o l i c y
statement on
dissemination
of off-label use
information.
WLF Off-Label
Use Suit Heats Up
enterprise.
The WLF originally
"They must think we're dopes. They've been
taking comments on this issue for three years and
then after we sue them- they ask for more time to
get more comments. The FDA knows full well
that it has in place a policy that inhibits the flow
of truthful information about off-label uses of
drugs and devices they have allowed on the
market. Basic honesty requires FDA to own up to
that policy in court. We're going to give them
that opportunity."
The crux of
the WLF
argument is
that the FDA's
restriction on
the dissemination of truthful information
regarding off-label uses of drugs and medical
devices violates the First Amendment rights of
Food & Drug
Insider Report
Richard Samp
WLF Chief Counsel
Volume 4, No. 18
F D A
regulations
require FDA
to answer
c i t i z e n
petitions
withi.r. 6
months or
else by law a
petition is
deemed to be
denied. The
FDA never
responded to
the WLF
petition, and,
three months
ago (June 13)
the WLF filed
suit in federal
district court
in Washington, D.C., to have the FDA draft
policy statement invalidated.

In a bizarre effort to buy time, the FDA's
erstwhile Deputy Commissioner Michael Taylor
whipped off a one-page letter to the WLF asking
for additional time to respond to the WLF
petition -- one month after WLF had sued FDA!
The FDA brain trust said they wanted to publish
notice of the WLF petition in the Federal
Register, get comments on it, and then respond
to the WLF petition. Although they had received
the WLF petition nine months earlier, Deputy
Commissioner Taylor 'fessed up that, "The
agency initially planned to publish [such a]
notice earlier, but was unable to do so due to
other agency priorities."
The WLF slam-dunked the agency's request to
postpone the FDA policy's day of reckoning in
court in a scathing July 21 press release,
essentially telling the agency to put up or shut
up; i.e., revoke the policy or see you in court.
The FDA apparently got the message and filed
a Motion to Dismiss the WLF lawsuit in early
August. This past week the WLF responded to
the FDA motion with a 43-page Answer
opposing the FDA's Motion to Dismiss. Oral
arguments on the two side's competing motions
are likely to be heard within the next few weeks.
In support of WLF's legal position, an amicus
brief was filed by the Media Institute on behalf
of the Association of American Publishers, the
Radio and Television News Directors
Association, and the Thomas Jefferson Center
for the Protection of Free Expression.
After almost a year's wait, the pending court
action should finally set in motion a First
Amendment legal confrontation between FDA
and WLF that very likely will eventually be
decided by the Supreme Court. The WLF has
been eagerly awaiting its day in court - the FDA
has taken every opportunity to duck the issue.
FDIR's bet, take WLF and give the points.
